Panel of 18 Biochemical Tests Rapidly Identifies Staphylococcus
|
By Labmedica staff writers Posted on 18 Feb 2008 |
|
A panel of 18 tests has been launched for the biochemical identification of Staphylococcus species and related organisms isolated from human clinical specimens.
Called Remel RapID Staph Plus, the rapid manual identification system offers clinical laboratories of any size a valuable new diagnostic tool for an important group of opportunistic pathogens. All of the test wells are inoculated simultaneously and the panel is then incubated aerobically for four hours.
Resultant color reactions are easy to read and are used to identify the organism using the RapID Staph Plus color guide, which helps generate a numeric microcode. The microcode is entered into Windows-based software for organism identification. This user-friendly package contains a comprehensive database of 40 medically important Staphylococcus species and related organisms, and ranks identifications by probability (greater than 95% probability is required for species level identification), ensuring accuracy and reliability.
The RapID Staph Plus can identify Staphylococcus aureus and over 30 species of coagulase negative staphylococci (CNS) in addition to other related organisms. CNS are an increasingly important cause of nosocomial infections. They are the most common causal agents of bacteraemia in patients with indwelling medical devices and are one of the most common causes of septicemia in pediatric patients.
RapID Staph Plus was developed by Oxoid (Basingstoke, UK
Julie Elston, clinical products application manager at Oxoid, commented, "The serious nature of bacteraemia means that there is little time to spare in determining the best course of action. Long delays simply are [not] acceptable and, as a result, the empiric use of agents such as vancomycin is common. RapID Staph Plus gives rapid, same-day results, allowing appropriate therapy to be determined more quickly and providing an opportunity for the use of vancomycin to be restricted to only when it is absolutely necessary.”
Oxoid's RapID range includes products for the identification of oxidase-negative Enterobacteriaceae, anaerobic bacteria, Gram-negative glucose non-fermenters, Corynebacterium species, Neisseria and Haemophilus (common in urinary infections), yeasts and related organisms, and Streptococci and related organisms.
Related Links:
Oxoid
Called Remel RapID Staph Plus, the rapid manual identification system offers clinical laboratories of any size a valuable new diagnostic tool for an important group of opportunistic pathogens. All of the test wells are inoculated simultaneously and the panel is then incubated aerobically for four hours.
Resultant color reactions are easy to read and are used to identify the organism using the RapID Staph Plus color guide, which helps generate a numeric microcode. The microcode is entered into Windows-based software for organism identification. This user-friendly package contains a comprehensive database of 40 medically important Staphylococcus species and related organisms, and ranks identifications by probability (greater than 95% probability is required for species level identification), ensuring accuracy and reliability.
The RapID Staph Plus can identify Staphylococcus aureus and over 30 species of coagulase negative staphylococci (CNS) in addition to other related organisms. CNS are an increasingly important cause of nosocomial infections. They are the most common causal agents of bacteraemia in patients with indwelling medical devices and are one of the most common causes of septicemia in pediatric patients.
RapID Staph Plus was developed by Oxoid (Basingstoke, UK
Julie Elston, clinical products application manager at Oxoid, commented, "The serious nature of bacteraemia means that there is little time to spare in determining the best course of action. Long delays simply are [not] acceptable and, as a result, the empiric use of agents such as vancomycin is common. RapID Staph Plus gives rapid, same-day results, allowing appropriate therapy to be determined more quickly and providing an opportunity for the use of vancomycin to be restricted to only when it is absolutely necessary.”
Oxoid's RapID range includes products for the identification of oxidase-negative Enterobacteriaceae, anaerobic bacteria, Gram-negative glucose non-fermenters, Corynebacterium species, Neisseria and Haemophilus (common in urinary infections), yeasts and related organisms, and Streptococci and related organisms.
Related Links:
Oxoid
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Nutating Mixer
Enduro MiniMix
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Latest Microbiology News
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Molecular Diagnostics
view channel
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Pathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
